{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:07Z","timestamp":1791923107250,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ccell.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:35:21Z","timestamp":1650537321000},"page":"494-508.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Bouffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schmidts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-5517","authenticated-orcid":false,"given":"Max","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-5862","authenticated-orcid":false,"given":"Marc","family":"Wehrli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korneel","family":"Grauwet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Horick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.04.001_bib2","unstructured":"Actavis_Pharma, S.P.S. Azacitidine [package Insert]. U.S. Food and Drug Administration"},{"key":"10.1016\/j.ccell.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T\u00a0cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","article-title":"A distinct transcriptional Program in human CAR T\u00a0cells bearing the 4-1BB signaling domain revealed by scRNA-seq","volume":"28","author":"Boroughs","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.4049\/jimmunol.152.4.1756","article-title":"The cloning of CD70 and its identification as the ligand for CD27","volume":"152","author":"Bowman","year":"1994","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/eji.201545749","article-title":"T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs","volume":"45","author":"Burchill","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2022.04.001_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136012","article-title":"A rational mouse model to detect on-target, off-tumor CAR T\u00a0cell toxicity","volume":"5","author":"Castellarin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccell.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.bbamcr.2017.03.010","article-title":"Matrix metalloproteinases - from the cleavage data to the prediction tools and beyond","volume":"1864","author":"Cieplak","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omto.2018.12.009","article-title":"Two-dimensional regulation of CAR-T cell therapy with orthogonal switches","volume":"12","author":"Duong","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ccell.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s10637-010-9459-6","article-title":"Kit inhibitor APcK110 extends survival in an AML xenograft mouse model","volume":"29","author":"Faderl","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ccell.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2022.04.001_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ccell.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T\u00a0cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T\u00a0cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping functional avidity of CAR-T cells: affinity, avidity and antigen density that regulate response","volume":"20","author":"Greenman","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2022.04.001_bib23","first-page":"145","article-title":"Venetoclax-based therapies for acute myeloid leukemia. Best practice & research","volume":"32","author":"Guerra","year":"2019","journal-title":"Clin. Haematol."},{"key":"10.1016\/j.ccell.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T\u00a0cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.04.001_bib26","article-title":"Chimeric antigen receptor (CAR) T\u00a0cell therapy in acute myeloid leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib27","first-page":"40","article-title":"Primary analysis of Zuma-5: a phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-142957","article-title":"Loss of TET2 uncouples proliferative and effector functions in CAR T\u00a0cells","volume":"136","author":"Jain","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2017","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ccell.2022.04.001_bib31","first-page":"742","article-title":"CD70- a new tumor specific biomarker for renal cell carcinoma","volume":"65","author":"Junker","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.exphem.2006.10.018","article-title":"Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells","volume":"35","author":"Kato","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ccell.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ccell.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T\u00a0cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.04.001_bib35","doi-asserted-by":"crossref","first-page":"19123","DOI":"10.18632\/oncotarget.24919","article-title":"Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells","volume":"9","author":"Kitajima","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccell.2022.04.001_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.1813666116","article-title":"Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome","volume":"116","author":"Leung","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A."},{"key":"10.1016\/j.ccell.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00253-015-6985-3","article-title":"Construction of a linker library with widely controllable flexibility for fusion protein design","volume":"100","author":"Li","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ccell.2022.04.001_bib38","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T\u00a0cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V126.23.3778.3778","article-title":"First-in-Man CD123-specific chimeric antigen receptor-modified T\u00a0cells for the treatment of refractory acute myeloid leukemia","volume":"126","author":"Luo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T\u00a0cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.04.001_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib44","series-title":"FDA Suspends UCART123 Trials after Patient Death","author":"Melao","year":"2017"},{"key":"10.1016\/j.ccell.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15818","article-title":"Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine","volume":"185","author":"Nahas","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ccell.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood-2018-99-118302","article-title":"Argx-110 targeting CD70, in combination with azacitidine, shows favorable safety profile and promising anti-leukemia activity in newly diagnosed AML patients in an ongoing phase 1\/2 clinical trial","volume":"132","author":"Ochsenbein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.oraloncology.2018.01.024","article-title":"CD70 as a target for chimeric antigen receptor T\u00a0cells in head and neck squamous cell carcinoma","volume":"78","author":"Park","year":"2018","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ccell.2022.04.001_bib51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic Combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2022.04.001_bib53","article-title":"The metalloproteinase inhibitor Prinomastat reduces AML growth, prevents stem cell loss and improves chemotherapy effectiveness","author":"Pirillo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2022.04.001_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019000050","article-title":"gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T\u00a0cells in multiple myeloma","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib55","unstructured":"Pubchem. PubChem Compound Summary for CID 9444, Azacitidine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Azacitidine"},{"key":"10.1016\/j.ccell.2022.04.001_bib56","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib57","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/MCB.06458-11","article-title":"The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand","volume":"32","author":"Richter","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ccell.2022.04.001_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib59","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79A","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"10.1016\/j.ccell.2022.04.001_bib61","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-14-1425","article-title":"pVHL\/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma","volume":"21","author":"Ruf","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib63","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T\u00a0cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib64","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2022.04.001_bib65","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2022.04.001_bib66","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T\u00a0cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib67","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2019-131024","article-title":"Single chain variable fragment linker length regulates CAR Biology and T\u00a0cell efficacy","volume":"134","author":"Singh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2022.04.001_bib69","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.04.001_bib70","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T\u00a0cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.04.001_bib71","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1107\/S2053230X17005957","article-title":"Crystal structure of CD27 in complex with a neutralizing noncompeting antibody","volume":"73","author":"Teplyakov","year":"2017","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.ccell.2022.04.001_bib72","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer cell"},{"key":"10.1016\/j.ccell.2022.04.001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ccell.2022.04.001_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao4910","article-title":"Structural principles of tumor necrosis factor superfamily signaling","volume":"11","author":"Vanamee","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ccell.2022.04.001_bib75","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.04.001_bib76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T\u00a0cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ccell.2022.04.001_bib77","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.04.001_bib78","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T\u00a0cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.04.001_bib79","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.4049\/jimmunol.0802597","article-title":"Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand","volume":"183","author":"Wyzgol","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2022.04.001_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-016-0337-3","article-title":"DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1","volume":"9","author":"Xu","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ccell.2022.04.001_bib81","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.7150\/jca.30223","article-title":"Up-regulation of EMT-related gene VCAN by NPM1 mutant-driven TGF-\u03b2\/cPML signalling promotes leukemia cell invasion","volume":"10","author":"Yang","year":"2019","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ccell.2022.04.001_bib82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3816\/CLML.2011.n.041","article-title":"Matrix metalloproteinase-8 is overexpressed in Waldenstr\u00f6m's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27","volume":"11","author":"Zhou","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082200157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082200157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:07:14Z","timestamp":1761523634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082200157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S153561082200157X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2022.04.001","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}